The University of Texas MD Anderson Cancer Center
MD Anderson is a public academic medical center and NCI-designated Comprehensive Cancer Center in Houston that delivers the full spectrum of cancer care, research, and education across nine Greater Houston locations, serving individual cancer patients domestically and patients from over 100 countries internationally.
- Company typePublic
- Founded1941
- HeadquartersHouston, United States
- Headcount5,001–10,000
- GTM typeB2C
- OfferingServices
What The University of Texas MD Anderson Cancer Center does
The University of Texas MD Anderson Cancer Center is a public academic medical center and one of 57 NCI-designated Comprehensive Cancer Centers, founded in 1941 and headquartered in the Texas Medical Center in Houston. The institution delivers the full spectrum of cancer care — including surgery, chemotherapy, radiation therapy, immunotherapy, CAR T cell therapy, bone marrow transplant, and targeted therapy — across its main campus and eight Greater Houston-area locations (West Houston, League City, Sugar Land, The Woodlands, Bellaire, Bastrop, Northwest Houston, and the Texas Medical Center). It has been ranked #1 in the nation for cancer care by U.S. News & World Report for 36 consecutive years, supports more NCI Specialized Programs of Research Excellence (SPOREs) than any other institution, and runs 1,099 CCSG program members across nine thematic research programs, 16 clinical site disease groups, and 13 full shared resources.
Revenue is generated primarily through patient-care services (diagnostics, treatments, surgeries, clinical trials) reimbursed under standard healthcare insurance models, supplemented by federal research grants (NIH, NCI), philanthropy (including $750M from the Dells and $150M from the Kinder Foundation in 2026), and state appropriations. Distribution is direct-to-consumer via the hospital and clinic network, augmented by the MD Anderson Cancer Network partner-hospital channel and an International Center serving referrals from over 100 countries through IAEA Rays of Hope and direct referrals.
The core technology stack combines clinical operations with proprietary research and AI platforms: the APOLLO longitudinal learning system for patient-data integration; the SOPHiA DDM Platform collaboration for next-generation sequencing analytics; the REDMOD AI system for early pancreatic-cancer detection from CT scans; the Path-IO deep-learning platform for immunotherapy-response prediction in NSCLC; the AI-driven Pan-Cancer Spatial Atlas of Tertiary Lymphoid Structures across 12 cancer types; novel therapies including CD94-targeted CAR T cell therapy, BetaBart radio-theranostic, tile-based radiation therapy (TBRT), HAMMR living-pharmacy platform, and the Institute for Cell Therapy Discovery & Innovation. Education is delivered through the School of Health Professions, graduate medical education, and 1,414 research trainees plus 1,775 clinical residents and fellows. The organization is governed as part of the University of Texas System and operates under NCI Comprehensive Cancer Center designation rather than as a commercial enterprise.
The University of Texas MD Anderson Cancer Center firmographics
Firmographics- Name
- The University of Texas MD Anderson Cancer Center
- Legal name
- The University of Texas MD Anderson Cancer Center
- Website
- https://mdanderson.org
- Company type
- Public
- Founded year
- 1941
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- MD Anderson is a public academic medical center and NCI-designated Comprehensive Cancer Center in Houston that delivers the full spectrum of cancer care, research, and education across nine Greater Houston locations, serving individual cancer patients domestically and patients from over 100 countries internationally.
- Ownership category
- akta.pro rank
The University of Texas MD Anderson Cancer Center industry classification
Industry- Product category
- Cancer Care Services
- NAICS
- Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111)
- SIC
- Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Oncology & Cancer Specialty Hospitals (HLAFAHAC)
- akta.pro secondary industries
- Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)
Keywords
Where The University of Texas MD Anderson Cancer Center is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices9 records
Markets served
The University of Texas MD Anderson Cancer Center business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales, Others
Revenue model
- Patient Care Services: MD Anderson generates revenue primarily through patient care services including diagnostic procedures, treatments, surgeries, chemotherapy, radiation therapy, immunotherapy, and clinical trials at its main campus and multiple Houston-area locations.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels5 records
The University of Texas MD Anderson Cancer Center product offering
Product offeringCore offering
MD Anderson is a comprehensive cancer center providing full-spectrum cancer treatment services including surgery, chemotherapy, radiation therapy (including proton therapy and tile-based radiation), immunotherapy, CAR T cell therapy, bone marrow transplantation, and targeted therapy to patients primarily in the Greater Houston area and internationally. The institution simultaneously runs one of the nation's largest oncology research portfolios spanning basic, translational, and clinical research, along with degree-granting schools and graduate medical education programs for oncology trainees.
Product overview
MD Anderson Cancer Center is a comprehensive cancer center offering a unified portfolio of clinical care services, research programs, and educational offerings. The institution provides full-spectrum cancer treatment including surgery, chemotherapy, radiation, immunotherapy, cellular therapy, CAR T, and targeted therapy through specialized care centers. Research infrastructure includes the Institute for Cell Therapy Discovery & Innovation, the Institute for Data Science in Oncology (IDSO), and the APOLLO adaptive learning platform. AI-powered offerings include the SOPHiA DDM™ Platform NGS test (co-developed with SOPHiA GENETICS), REDMOD AI for early pancreatic cancer detection, and Path-IO for immunotherapy response prediction. Additional programs include the Rare Tumor Initiative, Tumor Measurement Initiative, Program for T Cell Therapy, and MDACC Epigenomics Therapy Initiative (METI). The institution maintains data resources including the Rareview cBio Portal and Cancer InFocus visualization tools.
Differentiator
Problem solved
Functional benefit
Products and services
- Comprehensive Cancer Care Services Full spectrum of cancer treatment including surgery, chemotherapy, radiation therapy, immunotherapy, cellular therapy, CAR T cell therapy, bone marrow transplant, targeted therapy, and hormone therapy delivered at the main Texas Medical Center campus and Greater Houston area locations.
- Clinical Trials Program Hundreds of oncology clinical trials testing new treatments for both common and rare cancers, providing patients access to promising investigational therapies not available elsewhere, including participation in FDA real-time clinical trial programs.
- Specialized Cancer Care Centers and Clinics Disease-specific multidisciplinary care centers including the Leukemia Center, Lymphoma & Myeloma Center, Stem Cell Transplantation Center, Colorectal Center, Brain Metastases Clinic, and other specialized cancer care clinics.
- Cancer Prevention and Screening Services Risk assessment, screening, and diagnostic services through the Lyda Hill Cancer Prevention Center, including mammograms, cervical, colorectal, endometrial, liver, and lung cancer screenings, genetic testing, counseling, and management of hereditary cancer syndromes.
- Cancer Diagnostics and Pathology Comprehensive diagnostic services including imaging, laboratory testing, genomic testing, pathology review, and second opinion pathology services supporting cancer diagnosis and treatment planning.
- Oncology Education and Training Programs Degree-granting schools (School of Health Professions, MD Anderson UTHealth Houston Graduate School), graduate medical education, research training, postdoctoral training, and continuing professional education programs for medical professionals and trainees.
- International Patient Services International Center serving patients from over 100 countries with coordinated cancer care referrals, language services, and dedicated international patient support infrastructure.
- Second Opinion Services Formal second opinion appointments providing pathology review and clinical consultation for patients seeking expert diagnostic and treatment guidance from MD Anderson specialists.
- Supportive Care Services Palliative care, rehabilitation, and integrative medicine programs supporting cancer patients through treatment including the Supportive Care Center and Texas Community Bus Rounds outreach program.
Quantifiable outcome
- Tile-based radiation therapy (TBRT) reduced tumor recurrence rates to 1.3% compared to 15.4% with standard stereotactic radiation therapy, with median overall survival more than doubled to 42.5 months from 17.6 months
- +3 more outcomes
Companies that use The University of Texas MD Anderson Cancer Center
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles4 records
The University of Texas MD Anderson Cancer Center technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability13 records
Feature6 records
The University of Texas MD Anderson Cancer Center partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered major, core and strategic.
- QIMR BerghofermajorStrategic partnership to strengthen international collaboration in cell and gene therapy research, translation, workforce development, and advanced manufacturing through the CTMC Global Network Alliance. Combines QIMR Berghofer's translational research and advanced therapeutics manufacturing capabilities with CTMC's model for cell therapy development.
- CTMC (Cell Therapy Manufacturing Center)coreCollaboration on cell therapy development, manufacturing, regulatory strategy, and clinical translation. Partnership also supports NextGen, Australia's Centre for Cell and Gene Therapy Innovation and Manufacturing.
- Delphi DiagnosticsstrategicPublication collaboration validating Delphi's Endocrine Activity Index (EAI) test for predicting benefit from weekly paclitaxel in HR+/HER2- breast cancer patients based on GEICAM/9906 clinical trial analysis.
- IAEA (International Atomic Energy Agency)majorPartnership through IAEA's Rays of Hope cancer care initiative, with MD Anderson helping deliver training, technology, and expertise to countries with limited access to radiotherapy and medical imaging services. Over 100 countries have requested support.
- IBA (Ion Beam Applications S.A.)strategicSponsored research agreement to generate clinical and economic evidence on the cost-effectiveness of proton beam therapy compared to other treatment modalities. Research led by Dr. Matthew Ning and Dr. Iakovos Toumazis from MD Anderson's Institute for Data Science in Oncology.
- Ochsner HealthstrategicStrategic integration through partnership providing Ochsner Health access to early-phase clinical trials from UT MD Anderson Cancer Center as part of their 23rd Annual Research Week.
- Banner HealthstrategicPartnership with Banner Health's research enterprise conducting $80.5 million in research, providing MD Anderson access to clinical trial network and collaborative research opportunities.
- Rice UniversitystrategicJoint research partnership on AVB-001, an implantable cell-based therapy delivering interleukin-2 directly to ovarian cancer patients, reporting first-in-human Phase I trial results.
- TriSalus Life SciencesstrategicExpansion of existing collaboration for PREDICTT clinical trial evaluating Pressure-Enabled Drug Delivery (PEDD) technology with TriNav Infusion System in patients with liver tumors undergoing Y90 radioembolization therapy.
- Genprex Inc.strategicSponsored Research Agreement to study TROP2 and PTEN biomarkers that may predict patient response to Reqorsa Gene Therapy for non-small cell and small cell lung cancer treatment. Aims to refine patient selection strategies for Acclaim-1 and Acclaim-3 clinical trials.
- DuracytestrategicTechnology licensing partnership for Duracyte's 'living pharmacy' platform HAMMR. MD Anderson will conduct Phase I clinical trials for recurrent ovarian cancer patients, with Duracyte backed by over $100 million in research funding from DARPA, ARPA-H, NIH, and Gates Foundation.
- Radiopharm TheranosticscorePartnership through Radiopharm Ventures, LLC for BetaBart, a first-in-class radio-theranostic drug using Lutetium-177 targeting B7-H3 protein, with Phase I/II clinical trial underway.
- BostonGenestrategicCollaboration on FEASY study published in Cancer Discovery, demonstrating that RNA-based multiomic analysis identified new therapeutic targets for antibody-drug conjugates in patients with advanced solid tumors.
- Cancer Vaccine Coalitionstrategic$1 million grant for Phase II INTERCEPT-HER2 clinical trial using blood tests to detect circulating tumor DNA in HER2+ breast cancer patients and therapeutic vaccines to prevent recurrence.
- Io TherapeuticsstrategicCollaboration on RXR agonist compound IRX4204 for breast cancer prevention, published in Cancer Prevention Research, demonstrating prevention of ER-negative and triple-negative breast tumor formation.
- PranaX CorpstrategicTechnology licensing partnership for exosome-based regenerative biologics technology developed at MD Anderson and tested in Phase I clinical trial for pancreatic cancer.
- SOPHiA GENETICScoreStrategic collaboration to co-develop a next-generation sequencing oncology test built on SOPHiA DDM Platform and launch joint research programs focused on tumor evolution characterization, genomic testing reliability, and patient clinical trial matching.
- Pulse BiosciencesstrategicResearch collaboration to evaluate nPulse technology for treating thyroid cancers, with planned clinical study for papillary thyroid microcarcinoma and preclinical studies on anaplastic thyroid carcinoma.
- Lirum TherapeuticsstrategicRAPID platform clinical trial collaboration for treating relapsed/refractory Ewing Sarcoma and DSRCT in adolescent and young adult patients, with MD Anderson as trial lead.
- TheolyticsstrategicUS trial exploring intraperitoneal delivery of THEO-260 for platinum-resistant ovarian cancer in collaboration with Theolytics' OCTOPOD-IV trial.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
The University of Texas MD Anderson Cancer Center competitors and assessment
Company assessmentBroad incumbents
- Massachusetts General Hospital / Mass General Brigham: Harvard-affiliated multi-specialty academic system with a large cancer center. Comparable in proton therapy, research output, and clinical-trial breadth, though oncology is part of a wider portfolio.
- Stanford Medicine / Stanford Cancer Institute: Academic medical center with an NCI-designated cancer institute. Overlaps heavily on AI-driven pathology, genomics, immunotherapy, and clinical-trial innovation within a broader health system.
- Mayo Clinic: Multi-specialty academic health system with one of the largest U.S. cancer programs, co-developer with MD Anderson of REDMOD AI. Overlaps in research depth, brand reputation, and proton therapy but spans all specialties.
- Cleveland Clinic: Large multi-specialty academic health system with a major cancer institute (Taussig). Comparable in scale, brand, and clinical-trial infrastructure but broader than oncology-only.
Direct peers
- City of Hope: NCI Comprehensive Cancer Center in Southern California with a strong cell therapy and bone-marrow transplant franchise. Comparable size and direct overlap in CAR T, hematologic malignancies, and academic-industry partnerships.
- Fred Hutchinson Cancer Center: NCI Comprehensive Cancer Center in Seattle, originally founded as a research center, now integrated with UW Medicine. Direct peer in bone-marrow transplantation, cell therapy, and immunotherapy research.
- Dana-Farber Cancer Institute: NCI Comprehensive Cancer Center affiliated with Harvard/Brigham and Women's, focused exclusively on adult and pediatric oncology. Directly comparable in clinical trials volume, research output, and translational pipeline.
- H. Lee Moffitt Cancer Center & Research Institute: NCI Comprehensive Cancer Center in Tampa, FL, focused solely on oncology. Closely comparable mission (cancer-only specialty hospital + research institute), scale, and patient mix.
- Memorial Sloan Kettering Cancer Center: Largest U.S. cancer-only specialty hospital and NCI Comprehensive Cancer Center. Direct peer on every dimension: inpatient oncology, translational research, NCI SPOREs, CAR T development, and U.S. News cancer-care rankings.
- Johns Hopkins Medicine / Sidney Kimmel Comprehensive Cancer Center: NCI Comprehensive Cancer Center within Johns Hopkins, with overlapping strengths in translational research, CAR T, immunotherapy, and rare cancers. Same scale and academic medical-center operating model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
The University of Texas MD Anderson Cancer Center social profiles
Digital presenceThe University of Texas MD Anderson Cancer Center compliance and trust
Trust signalCompliance1 record
The University of Texas MD Anderson Cancer Center financial estimates
Financial estimateRevenue estimate
Valuation estimate
The University of Texas MD Anderson Cancer Center leadership team
Management profileNumber of profiles
Profiles10 records
The University of Texas MD Anderson Cancer Center subsidiaries and ownership
Company hierarchySubsidiaries5 records
The University of Texas MD Anderson Cancer Center funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The University of Texas MD Anderson Cancer Center M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The University of Texas MD Anderson Cancer Center
What does The University of Texas MD Anderson Cancer Center do?
MD Anderson is a comprehensive cancer center providing full-spectrum cancer treatment services including surgery, chemotherapy, radiation therapy (including proton therapy and tile-based radiation), immunotherapy, CAR T cell therapy, bone marrow transplantation, and targeted therapy to patients primarily in the Greater Houston area and internationally. The institution simultaneously runs one of the nation's largest oncology research portfolios spanning basic, translational, and clinical research, along with degree-granting schools and graduate medical education programs for oncology trainees.
Is The University of Texas MD Anderson Cancer Center a public or private company?
The University of Texas MD Anderson Cancer Center is a public company. It is classified as state government owned and is currently operating.
When was The University of Texas MD Anderson Cancer Center founded?
The University of Texas MD Anderson Cancer Center was founded in 1941. It employs 5,001 to 10,000 people.
Where is The University of Texas MD Anderson Cancer Center based?
The University of Texas MD Anderson Cancer Center is headquartered in Houston, United States, in the North America region.
How does The University of Texas MD Anderson Cancer Center make money?
One revenue line is on record: patient Care Services.
Who are The University of Texas MD Anderson Cancer Center's main competitors?
Broad incumbents on record are Massachusetts General Hospital / Mass General Brigham, Stanford Medicine / Stanford Cancer Institute, Mayo Clinic and Cleveland Clinic. Direct peers are City of Hope, Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center & Research Institute, Memorial Sloan Kettering Cancer Center and Johns Hopkins Medicine / Sidney Kimmel Comprehensive Cancer Center.
Does The University of Texas MD Anderson Cancer Center have an API?
No public API is recorded for The University of Texas MD Anderson Cancer Center.
What industry is The University of Texas MD Anderson Cancer Center in?
The University of Texas MD Anderson Cancer Center's product category is Cancer Care Services. Its primary akta.pro industry code is HLAFAHAC, Oncology & Cancer Specialty Hospitals, with a secondary code of HLAFAAAM, Hospital-Integrated Cancer Centers (Acute Oncology Programs). Its NAICS code is 622310 and its SIC code is 8060.